HRSA’s 340B Program Website Gets a New Look

HRSA 340B drug pricing program screenshots
HRSA refreshed its 340B drug pricing program website last week, the first major change in the site's appearance in about four years.

The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within the Health and Human Services Department (HHS) that runs the 340B drug discount program, refreshed the OPA site late last week. This is the

Read More »

AHF Sues Express Scripts Over Medicare Part D Reimbursement Claw Backs

Metal claw
AIDS Healthcare Foundation accuses Express Scripts of using its market power to wrongly claw back millions of dollars in Medicare drug reimbursement from pharmacies.

Pharmacy benefits manager Express Scripts unfairly uses a Medicare pharmacy ratings system to wrongly claw back millions of dollars in drug reimbursement from pharmacies participating in the Medicare Part D prescription drug program, AIDS Healthcare Foundation (AHF) alleges in a

Read More »

How One Leading 340B Services Company Has Taken Action to Stay Ahead of the Contract Pharmacy Restrictions Game

SPONSORED CONTENT

As the dispute with drug manufacturers over 340B contract pharmacies drags on, Sentry Data Systems has unveiled a suite of resources and capabilities to help covered entities decide on their next steps. It’s no coincidence that this has happened as Sentry integrates more closely as part of The Craneware Group.

As recent surveys have shown, the manufacturer exclusions on 340B contract pharmacies are taking an ever-growing bite out of the finances of our nation’s safety net hospitals and clinics. Meanwhile, covered entities are feeling the pressure to submit to the manufacturers’ demands to hand over contract pharmacy claims data to regain 340B pricing, even as the evidence we’ve seen suggests most participants are proceeding slowly after taking a wait-and-see approach — and they’re not always “all in.”

Sentry isn’t waiting. We’ve taken action to ensure our customers are educated and armed with information and other resources to make their own decision about whether to submit data. Our first steps

Read More »

News Alert

181 House Members Prod HHS to Start Fining Drug Makers for “Unlawful” 340B Overcharges Involving Contract Pharmacies

East elevation of the U.S. Capitol building
181 bipartisan U.S. House members on Friday urged HHS to quickly fine all drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.

One hundred eighty-one U.S. House members—144 Democrats and 37 Republicans—urged the Biden administration on Friday to quickly impose civil monetary penalties against all drug manufacturers that restrict access to 340B pricing when covered entities use contract pharmacies.

“Manufacturers have received

Read More »

Breaking News

In Big Win For 340B Hospitals, CMS Will Reverse Massive Drug Reimbursement Cut for 2023 and Seeks Input on Potential Remedies for Prior Years

CMS announced late today that they are reversing significant Medicare cuts to 340B hospitals.

The U.S. Centers for Medicare and Medicaid Services “fully anticipate[s]” applying a Medicare Part B reimbursement rate next year of average sales price ASP plus 6% to drugs and biologicals purchased through the 340B program, CMS announced late this afternoon.

Read More »

House GOP Task Force Apparently Takes a Pass on Making 340B Recommendations

Rep. Kevin Hern (R-OK) seated
A House GOP task force subcommittee chaired by Rep. Kevin Hern (R-Okla.) apparently has decided not to recommend 340B policies the party can advance if its takes control of the House following the November elections.

A U.S. House Republican task force assigned to develop proposals the party can advance if the GOP takes the majority in the November elections apparently chose not to make recommendations for the 340B program.

The Healthy Future Task Force’s affordability

Read More »

Feds Ask Appeals Court to Uphold HRSA’s 340B Program Violation Letters to Novo Nordisk and Sanofi

Seal of the U.S. Court of Appeals for the Third Circuit
The federal government wants the U.S. Third Circuit Court of Appeals to partially uphold and partially overturn a lower court's opinion in Novo Nordisk and Sanofi's consolidated 340B contract pharmacy cases.

A federal district judge was right to rule last November that drug makers Novo Nordisk and Sanofi may not tie strings to 340B pricing when providers use contract pharmacies, the federal government told a federal appeals court in Philadelphia last

Read More »

In Effort to Rein in High Prices, Another Big Player Jumps into the Insulin Market

Screenshot of Gov. Gavin Newsom in a television address
California Gov. Gavin Newsom (D) announced in a video message on Twitter that the state set aside $100 million to develop and manufacture its own low-cost insulin.

California will start making its own insulin under a state budget bill Gov. Gavin Newsom (D) signed June 30.

The bill includes $50 million to develop three low-cost biosimilar insulin products and another $50 million for a California-based insulin-manufacturing facility.

Read More »

HHS Warns Pharmacies Not to Turn Away Women Requesting Abortion Medication

U.S. Dept. of Health and Human Services Office for Civil RIghts Guidance to Nation's Retail Pharmacies title page
HHS issued guidance to retail pharmacies about their legal duty to fill prescriptions for drugs that can end or prevent pregnancy.

The U.S. Department of Health and Human Services issued guidance to retail pharmacies yesterday about their “unique role … in ensuring access to comprehensive reproductive health care services”—including filling prescriptions for drugs that can end or prevent pregnancy.

Mifepristone and

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report